AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$ABT

Ford Robert B sold $46.2M of ABT

Ford Robert B (CHAIRMAN AND CEO) sold 398,832 shares of ABBOTT LABORATORIES (ABT) at an average of $115.85 ($115.57–$116.19, $46.20M total) across 2 trades on 2026-08-25.

Original reporting
SEC EDGAR · Ford Robert B
Published Aug 27, 2026, 9:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 9:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ABT
Bearish
high confidence
Mentioned
$ABT
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABTBearishMed
01

Why it matters

The sale reduces insider ownership, potentially weakening confidence among shareholders.

02

Market read

A significant insider sell by the CEO is a material event that can influence short-term price action.

03

What to watch

No 10b5-1 plan; timing may be driven by personal liquidity needs rather than negative outlook.

Relevance 7/10Novelty 8/10Timing: filed 2026-08-27

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$ABTBearishHigh confidence
Context

Chairman and CEO Robert B. Ford sold 398,832 shares for $46.2M, reducing his stake to 306,461 shares.

Expected impact

Potential short-term downside pressure as market digests the sizable sell.

Evidence & confidence

The transaction size ($46M) is material for a large-cap pharma and the insider is the CEO, making it a notable market-moving event.

Market effects

Sector

May affect perception of Abbott Laboratories' governance and could influence biotech sector sentiment.

Regional

Primarily U.S. market impact; limited regional effect.

Global

Limited to investors tracking large-cap pharma insiders.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing unrelated to company fundamentals.

Key entities

  • Executive
    Robert B. Ford

    Chairman and CEO of Abbott Laboratories

  • Company
    Abbott Laboratories

    Global healthcare and diagnostics firm

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ABT insider trading history →

Related articles

$ABTMedAI 9/10

Abbott Touts Favorable Outcomes In Cardiovascular Device Trials

Abbott Laboratories (ABT) presented positive clinical trial results for two cardiovascular devices at a conference. The Amulet 360 LAA Occluder showed 96.3% complete closure in patients, with low complication rates. The SonicForce System achieved 97% procedural success in treating calcified coronary arteries. ABT shares rose 2.55% to $108.91.

finance.yahoo.com
$ABTMedAI 8/10

More than 98% of study patients had no stroke of the most common kind or blood-clot complication for a year.

Abbott (NYSE: ABT) presented one-year results from the VERITAS study of its Amulet 360 LAA Occluder, showing 98% of patients had no stroke or blood-clot complications. The device aims to reduce stroke risk in atrial fibrillation patients. Over 99% of patients had no pericardial effusion requiring intervention, and 98% had no cardiovascular-related mortality. The Amulet 360 features enhanced design for better LAA closure.

stocktitan.net
$ABTMed

Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke

Abbott (NYSE: ABT) presented one-year data from the VERITAS study on its Amulet 360 LAA Occluder, showing 96.3% closure rates and low stroke incidence in atrial fibrillation patients. The device is designed to reduce stroke risk and is approved for investigational use in the U.S. and CE Mark in Europe.

prnewswire.com
$ABTMedAI 8/10

Scans found heart-artery calcium fractures after an investigational sound-wave treatment

Abbott's investigational SonicForce Coronary IVL System showed positive results in the TECTONIC study, meeting safety and effectiveness endpoints. The study enrolled 335 patients with severe coronary calcification, reporting a 0.3% 30-day target lesion failure rate and 97% procedural success. The system uses acoustic pressure waves to crack calcium buildup in coronary arteries, potentially expanding Abbott's cardiovascular portfolio.

stocktitan.net
$ABTMedAI 9/10

Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System

Abbott (NYSE: ABT) reported positive 30-day results from its TECTONIC study of the investigational SonicForce Coronary IVL System, which met safety and effectiveness endpoints. The study showed a 0.3% target lesion failure rate and 97% procedural success in treating severe coronary calcification. The system uses acoustic pressure waves to crack calcium buildup in arteries, potentially expanding Abbott's portfolio of cardiovascular devices.

prnewswire.com